Back to Search
Start Over
Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors
- Source :
- Legal Monitor Worldwide. August 25, 2020
- Publication Year :
- 2020
-
Abstract
- (GlobeNewswire) - Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the Food and Drug Administration (FDA) granted [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Legal Monitor Worldwide
- Publication Type :
- News
- Accession number :
- edsgcl.633425581